Search
Now showing items 91-100 of 219
Evaluation of a urology specialist therapeutic radiographer implemented radiotherapy pathway for prostate cancer patients.
(ELSEVIER SCI LTD, 2021-04-15)
INTRODUCTION: The role of the Urology Specialist Therapeutic Radiographer (USTR) was introduced to support a busy NHS uro-oncology practice. Key objectives were to improve patient preparedness for and experience of ...
Androgen receptor binding sites enabling genetic prediction of mortality due to prostate cancer in cancer-free subjects.
(NATURE PORTFOLIO, 2023-08-23)
Prostate cancer (PrCa) is the second most common cancer worldwide in males. While strongly warranted, the prediction of mortality risk due to PrCa, especially before its development, is challenging. Here, we address this ...
Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.
(LIPPINCOTT WILLIAMS & WILKINS, 2023-11-10)
PURPOSE: The surrogacy of biochemical recurrence (BCR) for overall survival (OS) in localized prostate cancer remains controversial. Herein, we evaluate the surrogacy of BCR using different surrogacy analytic methods. ...
How Low Can You Go? The Radiobiology of Hypofractionation.
(ELSEVIER SCIENCE LONDON, 2022-05-01)
Hypofractionated radical radiotherapy is now an accepted standard of care for tumour sites such as prostate and breast cancer. Much research effort is being directed towards more profoundly hypofractionated (ultrahypofractionated) ...
Imaging features of the evolving patterns of metastatic prostate cancer.
(W B SAUNDERS CO LTD, 2022-02-01)
The pattern of metastases in prostate cancer (PC) is evolving. Increased use of imaging, newer imaging techniques with higher sensitivity for disease detection and patients receiving multiple lines of novel therapies with ...
MR-guided radiotherapy for prostate cancer: state of the art and future perspectives.
(BRITISH INST RADIOLOGY, 2022-03-01)
Advances in radiotherapy technology have increased precision of treatment delivery and in some tumour types, improved cure rates and decreased side effects. A new generation of radiotherapy machines, hybrids of an MRI ...
Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art.
(RADIOLOGICAL SOC NORTH AMERICA (RSNA), 2019-08-01)
The management of advanced prostate cancer has changed substantially with the availability of multiple effective novel treatments, which has led to improved disease survival. In the era of personalized cancer treatments, ...
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
(ELSEVIER, 2022-07-01)
BACKGROUND: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. ...
A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.
(WILEY, 2021-07-01)
BACKGROUND: Inflammation and one of its mediators, NF-kappa B (NFκB), have been implicated in prostate cancer carcinogenesis. We assessed whether germline polymorphisms associated with NFκB are associated with the risk of ...
Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
(FUTURE MEDICINE LTD, 2021-11-01)
Androgen deprivation therapy using gonadotropin-releasing hormone (GnRH) analogues is standard treatment for intermediate and advanced prostate cancer. GnRH agonist therapy results in an initial testosterone flare, and ...